Clever-1 inhibition in human cancer: consequences and control of bexmarilimab-induced macrophage activation

Read full text Summarise with VIRAT
Authors: Jenna H. Rannikko
Cited by: 0
References: 593

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cancer immunotherapy enhances the immune system’s ability to eliminate cancer cells for remarkable efficacy, but new therapies are needed to combat treatment resistance. Tumor-associated macrophages (TAMs) drive cancer progression largely through immunosuppression, and inhibiting their immunoregulatory scavenger receptor Clever-1 restores anti-tumor immunity in mice. A Clever-1-blocking humanized antibody bexmarilimab, developed to exploit this mechanism, entered first-in-human clinical testing for advanced solid tumors (MATINS trial) in 2018. This thesis aimed to elucidate the immunological consequences of human macrophage Clever-1 blockade and to identify regulators of bexmarilimab treatment sensitivity. The presented transcriptomic, single-cell and spatially resolved analyses of clinical patient samples, patient-derived cells and tumor explants provide the first functional characterization of Clever-1 inhibition in human cancer. We discovered bexmarilimab to disrupt tolerogenic lipid metabolism pathways and lysosomal acidification in monocytes and macrophages, resulting in their pro-inflammatory activation. In patients, monocyte and TAM reprogramming was accompanied by interferon and T-cell responses, both in the circulation and within tumors demonstrating disease stabilization. Similar immune responses occurred in one third of bexmarilimab-treated patient-derived cancer models, enabling recognition of bexmarilimab-sensitive tumor explant cultures with a gene signature identified in this thesis. Patient-derived cancer models additionally revealed that bexmarilimab-treated TAMs secrete CXCL10 for T-cell recruitment and that the tumor secretome regulates bexmarilimab responses more strongly than macrophage origin or cellular neighborhoods. Across the studies, bexmarilimab-induced immune responses were principally observed in interferon-poor tumor microenvironments, while chronic interferon priming impaired bexmarilimab-mediated macrophage activation. Additionally, responsive tumors had abundant intratumoral Clever-1+ TAMs and low PD-L1 expression, while lacking IL4I1+ TAMs and regulatory T cells. In conclusion, bexmarilimab activates macrophage- and T-cell-mediated immunity in non-inflamed tumors, which are mostly resistant to the current T-cell directed cancer immunotherapies effective in T-cell- and interferon-rich tumors.

Fields of Study & Subjects

Immune cells in cancer Cancer Immunotherapy and Biomarkers Phagocytosis and Immune Regulation

Publication details

Journal / source
UTUPub (University of Turku)
Publication date
17 March 2026
Language
EN
Document type
Thesis